459 related articles for article (PubMed ID: 37518857)
1. Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.
Korzun T; Moses AS; Diba P; Sattler AL; Olson B; Taratula OR; Pejovic T; Marks DL; Taratula O
Small; 2023 Jul; ():e2301776. PubMed ID: 37518857
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development.
Lu M; Xing H; Zheng A; Huang Y; Liang XJ
Acc Chem Res; 2023 Feb; 56(3):224-236. PubMed ID: 36624086
[TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
4. Resveratrol in the Treatment of Gynecological Cancer: Mechanisms and Therapeutic Potential.
Mozafaryan MJ; Rezaei P; Masoudpoor F; Bahri A; Samini M; Farkhondeh T; Pourhanifeh MH; Samarghandian S
Curr Med Chem; 2024 May; ():. PubMed ID: 38706364
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Unraveling role of ubiquitination in drug resistance of gynecological cancer.
Yu L; Chen Z; Wu Y; Xu M; Zhong D; Xu H; Zhu W
Am J Cancer Res; 2024; 14(5):2523-2537. PubMed ID: 38859858
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
[TBL] [Abstract][Full Text] [Related]
8. Innovative developments and emerging technologies in RNA therapeutics.
Halloy F; Biscans A; Bujold KE; Debacker A; Hill AC; Lacroix A; Luige O; Strömberg R; Sundstrom L; Vogel J; Ghidini A
RNA Biol; 2022; 19(1):313-332. PubMed ID: 35188077
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers.
Xu T; Yu S; Zhang J; Wu S
J Hematol Oncol; 2021 Oct; 14(1):181. PubMed ID: 34717710
[TBL] [Abstract][Full Text] [Related]
10. Safe and Effective Kinase Inhibitors for the Treatment of Gynecological Cancers: In Silico Approach.
Patil VM; Kumar A; Anand V; Bansal P; Masand N
Curr Drug Metab; 2021; 22(7):537-549. PubMed ID: 33797363
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
12. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
Gu W; Meng F; Haag R; Zhong Z
J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience.
Sawada K; Nakayama K; Nakamura K; Yoshimura Y; Razia S; Ishikawa M; Yamashita H; Ishibashi T; Sato S; Kyo S
Healthcare (Basel); 2021 Oct; 9(10):. PubMed ID: 34683075
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine for urologic cancers: diagnosis and management.
Li C; Zeng X; Qiu S; Gu Y; Zhang Y
Semin Cancer Biol; 2022 Nov; 86(Pt 2):463-475. PubMed ID: 35660001
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract][Full Text] [Related]
16. An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group.
Shigeta S; Shimada M; Suzuki S; Kajiyama H; Oda K; Takehara K; Mandai M; Aoki D; Enomoto T; Okamoto A
JMA J; 2023 Oct; 6(4):527-531. PubMed ID: 37941704
[TBL] [Abstract][Full Text] [Related]
17. Application of natural polysaccharides and their novel dosage forms in gynecological cancers: therapeutic implications from the diversity potential of natural compounds.
Li Y; Zhang C; Feng L; Shen Q; Liu F; Jiang X; Pang B
Front Pharmacol; 2023; 14():1195104. PubMed ID: 37383719
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine in cancer therapy.
Fan D; Cao Y; Cao M; Wang Y; Cao Y; Gong T
Signal Transduct Target Ther; 2023 Aug; 8(1):293. PubMed ID: 37544972
[TBL] [Abstract][Full Text] [Related]
19. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
20. Therapeutic potential of Curcuma oil and its terpenoids in gynecological cancers.
Zhang Y; Peng F; Yu C
Biomed Pharmacother; 2023 Jan; 157():114016. PubMed ID: 36395609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
